CD86 and plasma cell myeloma: By investigating individual interactions, we observed a frequent downregulation of pair of genes in immunomodulation in patients with low immune reactive, including CD86-CD28, TNFRSF10A-TNFSF10, CD74-APP/COPA/MIF, HLA-C-FAM3C and HLA-E-NKG2C (KLRC2), while upregulated pro-myeloma gene pairs including TGFB1-TGFBR2/TGFBR3, LGALS9-CD44 and CD47-SIRPA (Additional file 1: Fig. S12B).